Monoclonal antibodies can affect complement deposition on the capsule of the pathogenic fungus Cryptococcus neoformans by both classical pathway activation and steric hindrance

被引:24
作者
Zaragoza, Oscar
Casadevall, Arturo
机构
[1] Albert Einstein Coll Med, Dept Immunol & Microbiol, Bronx, NY 10461 USA
[2] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
关键词
D O I
10.1111/j.1462-5822.2006.00753.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The capsule of the human pathogenic fungus Cryptococcus neoformans presents the immune system with a formidable problem for phagocytosis. Capsule-mediated activation of the alternative complement (C) pathway results in component 3 (particularly, C3) binding to the capsule near the cell wall surface. Hence, for cells with large capsule, C3 cannot interact with the complement receptor (CR) and is not opsonic. However, C activation in either immune serum or in the presence of monoclonal antibody (mAb) to capsular polysaccharide localizes C3 to the capsular edge. When C. neoformans cells were coated with both C and antibody (Ab) opsonins, Ab bound first and promoted C3 deposition at the edge of the capsule. The mechanism for the Ab-mediated change in C3 localization to the capsule edge involved both classical C pathway activation and steric hindrance preventing C3 penetration into the capsule. The change in C3 localization changed the mode of phagocytosis in macrophages, such that localizing C3 at the edge of the capsule allowed phagocytosis through C3-CR3 and C3-CR4 interactions, which did not occur in serum without Ab. These findings reveal a new mechanism of Ab action whereby Abs affect the location of C3 and its interaction with its receptor in macrophages depending on the immunoglobulin concentration.
引用
收藏
页码:1862 / 1876
页数:15
相关论文
共 57 条
[1]   LOCALIZATION OF COMPLEMENT COMPONENT-3 ON STREPTOCOCCUS-PNEUMONIAE - ANTI-CAPSULAR ANTIBODY CAUSES COMPLEMENT DEPOSITION ON THE PNEUMOCOCCAL CAPSULE [J].
BROWN, EJ ;
JOINER, KA ;
COLE, RM ;
BERGER, M .
INFECTION AND IMMUNITY, 1983, 39 (01) :403-409
[2]   A QUANTITATIVE-ANALYSIS OF THE INTERACTIONS OF ANTI-PNEUMOCOCCAL ANTIBODY AND COMPLEMENT IN EXPERIMENTAL PNEUMOCOCCAL BACTEREMIA [J].
BROWN, EJ ;
HOSEA, SW ;
HAMMER, CH ;
BURCH, CG ;
FRANK, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1982, 69 (01) :85-98
[3]   The classical pathway is the dominant complement pathway required for innate immunity to Streptococcus pneumoniae infection in mice [J].
Brown, JS ;
Hussell, T ;
Gilliland, SM ;
Holden, DW ;
Paton, JC ;
Ehrenstein, MR ;
Walport, MJ ;
Botto, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (26) :16969-16974
[4]   Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies [J].
Casadevall, A ;
Cleare, W ;
Feldmesser, M ;
Glatman-Freedman, A ;
Goldman, DL ;
Kozel, TR ;
Lendvai, N ;
Mukherjee, J ;
Pirofski, LA ;
Rivera, J ;
Rosas, AL ;
Scharff, MD ;
Valadon, P ;
Westin, K ;
Zhong, ZJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (06) :1437-1446
[5]   MONOCLONAL-ANTIBODY BASED ELISAS FOR CRYPTOCOCCAL POLYSACCHARIDE [J].
CASADEVALL, A ;
MUKHERJEE, J ;
SCHARFF, MD .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 154 (01) :27-35
[6]  
Casadevall A, 1998, CRYPTOCOCCUS NEOFORM, DOI DOI 10.1128/9781555818241
[7]   COMPLEMENTATION OF A CAPSULE-DEFICIENT MUTATION OF CRYPTOCOCCUS-NEOFORMANS RESTORES ITS VIRULENCE [J].
CHANG, YC ;
KWONCHUNG, KJ .
MOLECULAR AND CELLULAR BIOLOGY, 1994, 14 (07) :4912-4919
[8]   The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays [J].
Cleare, W ;
Casadevall, A .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 1998, 5 (02) :125-129
[9]  
DIAMOND RD, 1973, P SOC EXP BIOL MED, V144, P312, DOI 10.3181/00379727-144-37580
[10]  
DIAMOND RD, 1974, J IMMUNOL, V112, P2260